2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Attrition rates of failed Phase 3 candidates<br />
reveals POC Paradigm benefits<br />
OBJECTIVITY AND AND ROBUSTNESS OF<br />
REGISTERABLE OF BIOMARKER ENDPOINT<br />
H<br />
Source: Evaluate; Pharmaprojects; Factiva;<br />
literature search; McKinsey analysis; I. Kola<br />
High Biomarker<br />
Low POC<br />
Attrition rate 63%<br />
LEAST DESIRABLE QUADRANT<br />
FOR PORTFOLIO IN LATE STAGE<br />
DEVELOPMENT<br />
42% of Phase 3 trials fail*<br />
DESIRED QUADRANT FOR MOST<br />
OF PORTFOLIO<br />
Attrition rate 25%<br />
High POC<br />
Low Biomarker<br />
Attrition rate 70% Attrition rate 37%<br />
L<br />
P.O.C IN MAN<br />
H<br />
Note: Includes aggregate attrition rates for following TAs: CNS, Endocrine, CV, ID, Oncology, and<br />
Respiratory. All figures are rounded<br />
49
Change language